Rasilez and Slow rhr for Men aged 60+ (a phase IV clinical study of FDA data)

Summary:

Slow rhr is found for men aged 60+ who take Rasilez (aliskiren hemifumarate). This study is created by eHealthMe based on reports of 1,342 men aged 60+ from the FDA, and is updated regularly. The information that eHealthMe analyzes includes:

Time on Rasilez when people have Slow rhr
Top conditions
Top co-used drugs
Top other side effects

On Mar, 05, 2026

1,342 men aged 60+ reported to have side effects when taking Rasilez.
Among them, 35 people (2.61%) have Slow rhr

What is Rasilez?

Rasilez has active ingredients of aliskiren hemifumarate. It is often used in high blood pressure. eHealthMe is studying from 6,001 Rasilez users. Check the latest studies of Rasilez.

What is Slow rhr?

Slow rhr is found to be associated with 2,993 drugs and 3,004 conditions by eHealthMe. Check the latest studies of Slow rhr.

Number of reports submitted per year:

Could Rasilez cause Slow rhr in men aged 60+?

Time on Rasilez when people have Slow rhr *

Severity of Slow rhr

n/a

How people recovered from Slow rhr

n/a

Top conditions involved for these people *:

You may use this to check any potential undetected conditions.

Hyperuricaemia (level of uric acid in the blood that is abnormally high): 7 people, 20.00%
High Blood Cholesterol: 4 people, 11.43%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 8.57%
Cardiac Failure: 3 people, 8.57%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 3 people, 8.57%
Diabetes: 3 people, 8.57%
Cardiac Failure Chronic: 2 people, 5.71%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 2 people, 5.71%
Supraventricular Extrasystoles (premature electrical impulse in the heart, generated above the level of the ventricle): 2 people, 5.71%
Dyslipidaemia (abnormal amount of lipids): 1 person, 2.86%

Top co-used drugs for these people *:

You may use this to check any potential interacting drugs.

Top other side effects for these people *:

You may use this to check any potential undetected side effects.

Hyperkalemia (damage to or disease of the kidney): 14 people, 40.00%
Blood Glucose Increased: 8 people, 22.86%
Chronic Renal Failure (kidney failure): 7 people, 20.00%
Loss Of Consciousness: 7 people, 20.00%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 5 people, 14.29%
Blood Creatinine Increased: 5 people, 14.29%
Blood Urea Increased: 5 people, 14.29%
Renal Function Test Abnormal: 5 people, 14.29%
Atrioventricular Block Complete (heart block complete): 5 people, 14.29%
Hepatic Function Abnormal: 4 people, 11.43%

* Approximation only. Some reports may have incomplete information.

Do you take Rasilez and have Slow rhr?

- Check whether Slow rhr is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies:

Rasilez and Slow rhr

How the study uses the data?

The study is based on (applicable) gender, age, aliskiren hemifumarate (the active ingredients of Rasilez) and Rasilez (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.